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Abstract. Artemisinin combination therapies are available in private outlets, but patient adherence might be
compromised by poor advice from dispensers. In this cluster randomized trial in drug shops in Tanzania, 42 of 82
selected shops were randomized to receive text message reminders about what advice to provide when dispensing
artemether-lumefantrine (AL). Eligible patients purchasing AL at shops in both arms were followed up at home and
questioned about each dose taken. Dispensers were interviewed regarding knowledge of AL dispensing practices and
receipt of the malaria-related text messages. We interviewed 904 patients and 110 dispensers from 77 shops. Although
there was some improvement in dispenser knowledge, there was no difference between arms in adherence measured as
completion of all doses (intervention 68.3%, control 69.8%, p [adjusted] = 0.6), or as completion of each dose at the
correct time (intervention 33.1%, control 32.6%, p [adjusted] = 0.9). Further studies on the potential of text messages
to improve adherence are needed.
INTRODUCTION
Patient adherence to treatment is an important step in
ensuring the effectiveness of artemisinin-based combination
therapies (ACTs) for malaria.1 Incomplete adherence to recom-
mended treatment can result in poor clinical outcomes, under-
mine the effectiveness of case management as a tool for malaria
control, and may contribute to the selection of drug-resistant
malaria parasites.2,3 ACTs are first-line treatment of Plasmo-
dium falciparum malaria in the public sector of most malaria-
endemic countries, with patient adherence reported to range
widely from39% to 100%.4,5Many patients seek care formalaria
in the private retail sector.6–9 The proportion of private sector
clients obtaining ACTs has increased over time as ACTs have
become more widely known, and their price has fallen, particu-
larly in settings where they have been subsidized by programs
such as the AffordableMedicines Facility-malaria (AMFm).10
Althoughaccess toeffective antimalarials in theprivate sector
may have increased, drug sellers may not always provide
patients with appropriate doses or advice, raising concerns
about patient adherence, though evidence is very limited. Only
five studies have specifically assessed patient adherence to anti-
malarials obtained in the private retail sector.11–15 Of these,
ACTs were used only in one study by Cohen and others
(2012)11 in Uganda, which reported 66% of patients seeking
care from drug shops were adherent. As ACTs become more
available in the private sector, it becomes increasingly important
to understand patient adherence and the effects of interven-
tions intended to improve adherence. Supporting interven-
tions, such as shopkeeper training, have previously succeeded
in increasing the proportion of patients who receive and com-
plete the recommended dose of non-ACT antimalarials,13,16
but such interventions have yet to be tested on a national scale
or applied to ACTs.
Mobile phones are a promising tool for the delivery of
healthcare interventions as coverage of mobile networks and
handset ownership increases.17–19 Text messaging, the least
expensive mobile phone function, has been used in malaria
control settings for commodity monitoring, disease surveil-
lance, and pharmacovigilance.20 In addition, a trial in public
health facilities in Kenya21 showed that 6 months of text mes-
sage reminders improved public health workers’ management
of pediatric malaria by 24% points immediately after the
intervention, and the improvements were sustained for at
least 6 months after the intervention was withdrawn. The text
message reminders were well accepted by health workers,22
inexpensive, and cost-effective.23
Given the concerns over inadequate patient adherence to
ACTs delivered through the private retail sector, and the
potential benefit of text-message interventions to enhance
adherence, we designed and completed a cluster randomized
trial in southern Tanzania to assess the effect of text message
reminders to drug shop workers on patient adherence to
artemether-lumefantrine (AL). We also evaluated the effect
of text messages on dispenser knowledge and advice.
The private retail sector in Tanzania is an important source
of treatment of malaria,24,25 and ACT availability in such
outlets increased after the implementation of AMFm in 2010.
Another key intervention in Tanzania’s private sector has
been the creation of accredited drug dispensing outlets
(ADDOs) by the Tanzania Food and Drug Administration
(TFDA) to improve regulation of drug shops and quality of
medicines. ADDOs are drug shops that have been upgraded
through a process of training and certification and are allowed
to sell a limited number of prescription-only drugs, including
some antibiotics and ACTs.26,27
METHODS
Study setting. The study was conducted in Mtwara, a rural
region in southeastern Tanzania with 35.5% of the population
in the lowest national wealth quintile.28 Prevalence of malaria
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among children 6–59 months of age in Mtwara was 17.4%
in the 2011–2012 HIV/AIDS and Malaria Indicator Survey29
and 23% in a survey of patients seeking treatment at private
drug shops.30 AL has been recommended as the first-line
treatment of malaria since 2004, although it was not available
in public health facilities until 2006. The recommended treat-
ment regimen is six doses of AL over 3 days, with 1–4 tablets
(20 mg artemether/120 mg lumefantrine) per dose depending
on the weight/age band. National guidelines state that the
second dose should be taken 8 hours after the first dose,
followed by the remaining doses morning and evening of the
second and third days.31
In Mtwara, ADDO accreditation commenced in 2006, and
officially only accredited drug stores are allowed to function. In
reality, a large number of non-accredited shops exist because of
a lack of training, unpaid fees, or administrative delays. These
shops are tolerated by regulating authorities and considered
“prospective ADDOs.” Before AMFm, ACTs were not com-
monly available in ADDOs in Mtwara, and dispenser training
on ACTs was limited, but ACT availability significantly
increased after AMFm implementation, with 88% of ADDOs
stocking ACTs in Mtwara in August 2011.32 To support
AMFm roll out, TFDA offered a 1 day refresher training that
included treatment of malaria with ACTs to dispensers with
previous nursing training in Mtwara in August 2011.
Sample size calculations. We based the sample size for this
two arm cluster randomized trial on data from the public
sector in Tanzania, where patient adherence to AL was 65–
98%(Khatib R, unpublished data).33–35 We assumed lower
adherence to AL obtained at ADDOs in Mtwara (60%) and
powered the study to detect a 15% point increase in the inter-
vention arm. We wanted to recruit a small number of patients
per cluster to reduce the potential bias caused by increasing
community awareness of the study’s objectives. Assuming a
coefficient of variation of 0.25, 80% power, 5% significance,
and 20% loss to follow-up, 13 patients from 36 outlets in each
arm were required, a total of 468 patients per arm.
Selection of study ADDOs. In May 2012, we conducted a
census of all drug shops in Mtwara (ADDOs or prospective
ADDOs). Data were collected on the characteristics of owners
and dispensers, ACT stocks and sales, and global positioning
system (GPS) coordinates. ADDOs were excluded from the
sampling frame if they had sold fewer than five antimalarial
treatments in the previous week, no dispensers used a mobile
phone, the shop was located on the border with Mozambique
or was not accessible, or the owner refused to participate
(Figure 1). The final sampling frame consisted of 131 ADDOs.
The 82 ADDOs were selected sequentially at random, with any
ADDOs within 400 m of a selected ADDO, or any ADDOs
where staff from a selected ADDO also worked, removed from
the sampling frame. The selected ADDOs were then stratified
by location in urban or rural wards, and the intervention
was randomly allocated to 29 of 57 urban ADDOs and 13 of
25 rural ADDOs.
Intervention design. We designed seven content messages
about advice that dispensers should provide when dispensing
AL (Figure 2). The messages were derived from the govern-
ment refresher training booklet and reflected the recom-
mended practices for dispensing AL. Messages were pilot
tested in ~20 ADDOs in a semi-urban district outside of
Dar es Salaam. Dispensers at these ADDOs were sent each
potential message in turn and asked to explain their understand-
ing of the meaning and relevance of each message. Dispensers
were also asked if they would find receipt of the messages
helpful, how often they would like to read the messages, and
whether complementary components such as quotes or ques-
tions would encourage reading. Phrasing and frequency of the
messages were adjusted based on feedback received during
the pilot.
Before sending the first message, the 42 ADDOs in Mtwara
randomized to the intervention arm were visited to invite
participation and collect an updated list of mobile numbers
for all dispensers. Messages began in July 2012 and were sent
in random order once per day Monday–Friday for the first
4 weeks, followed by once per day Monday, Wednesday, and
Friday for the next 10 weeks. Messages were written in
Swahili and scheduled in advance on an automated platform,
with each message paired with a different complementary
component each time to promote interest. Complementary
components consisted of inspirational quotes or proverbs or,
once per week, a quiz question on message content that
earned correct respondents free air time (500 TSH or $.30).
Over the 14-week period, 49 messages were sent to each of
60 dispensers, and detailed delivery reports were kept for
each message.
Data collection. From September through November 2012,
dispensers at ADDOs in the intervention and control arms
were visited by study supervisors and given a standard intro-
duction about study objectives. To limit patients’ awareness
of our primary interest in adherence, which could have led to
a biased assessment, dispensers were told we were studying
how patients chose to treat fever and would visit some, but
not all, patients at their homes. They were asked to fill out a
registration form for all patients purchasing any treatment of
fever, including the day and time of their ADDO visits, the
patients’ names, the drugs purchased, and a description of
where the patients lived. Dispensers were provided with blis-
ter packs of AL that they could then sell to patients needing
treatment of malaria. Study staff visited ADDOs every day to
check and collect registration forms for 1–3 weeks, or until
12–15 patients purchasing AL were registered if quicker.
Eligible patients who obtained AL were identified from the
registration forms and assigned patient identification numbers
(recorded on follow-up forms). Patients were followed up
~68–72 hours after their ADDO visit, according to a pre-
defined schedule, and all attempts to locate and interview
patients were recorded. Where written informed consent was
given, patients or their caregivers were asked about demo-
graphic and socioeconomic characteristics, treatment-seeking
history, illness symptoms, detailed information about each
dose of AL taken and the advice provided by the ADDO
dispenser. Blister packs were requested for a pill count, and
blood samples were collected for a blood smear and a malaria
rapid diagnostic test (mRDT) (Pf-specific from ICT Diagnos-
tics, Cape Town, South Africa). Blood smears were stained
in the field and transported to the Ifakara Health Institute,
where they were double-read by two microscopists blinded
to results from each other and the mRDT, with discrepant
results read by a third microscopist.
Adherence was defined in two ways.5 Patients were consid-
ered to have “verified completed treatment” if they reported
taking all doses by the time of the follow-up visit and a pill
count verified that no pills remained in the blister pack,
if available. The second, more stringent definition included
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a time component, based on patient reports of the time
each dose was taken using the Swahili times of day: “alfajiri”
(early morning), “asubuhi” (morning), “mchana” (afternoon),
“jioni” (evening), “usiku” (night), and “usiku sana” (late
night). Patients were considered to have “verified timely com-
pletion” if they took the second dose at the Swahili time of
day corresponding with 8 hours after the first dose, and then
took each of the remaining doses at the Swahili time of day
Figure 1. Consort-like style flow diagram of trial.
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corresponding with 12 hours after the previous dose, verified
by the absence of pills in the blister pack. For ease of reading,
we hereafter refer to these definitions as “completed treat-
ment” and “timely completion.”
After completion of patient interviews, dispensers working
at the study ADDOs were interviewed on ADDO character-
istics, demographics, receipt of study text messages, and
advice they would give to patients when dispensing AL. To
assess knowledge corresponding with message content, we
used an open-ended question, e.g., “I would like to ask about
which advice you think you should provide to a person of
any age taking treatment for malaria. For the following topics
(e.g., “when to take the second dose” or “what to do with the
pills if the patient feels better,” etc.) tell me if advice on this
topic is important or not, and if so, what advice you would
provide.” Responses were recorded verbatim and evaluated
by the study leader using predetermined criteria based on
message content.
Data entry and analysis.All patient and dispenser interview
data were collected using personal digital assistants, and data
extracted from study forms (census, registration, and follow-
up forms) were double entered into Microsoft Access data-
bases (Microsoft Corp., Redmond, WA). Data were analyzed
in Stata 11.0 (Stata Corporation, College Station, TX). Pri-
mary outcomes were analyzed by intention-to-treat. Compar-
ison of adherence was based on a t test of the proportion
adherent in each cluster. A list of potentially important con-
founders was identified a priori consisting of ADDO accredi-
tation certificate, number of customers purchasing ACTs in
the previous week, dispenser medical qualification, dispenser
training on ACTs, patient age, and patient education. Adjust-
ment for variables on this list found to be unbalanced between
arms was performed by fitting a logistic regression model to
the individual data and performing analysis on the aggregated
residuals, as described by Bennett and colleagues.37
Ethics. All questionnaires, consent forms, and other study
documents were translated into Swahili and piloted before
use. Written informed consent was collected from dispensers
before census, patient registration and interview, and from
patients or their caregivers prior to interview. The study pro-
tocol was approved by the ethical review boards of Ifakara
Health Institute and London School of Hygiene and Tropical
Medicine. The Centers for Disease Control and Prevention
(CDC) investigators provided technical assistance in design
and analysis but were not engaged in data collection. The trial
is registered with Current Controlled Trials, ISRCTN83765567.
RESULTS
Figure 1 shows the trial profile. Of the 82 randomized
ADDOs, 37 from the control arm and 40 from the interven-
tion arm participated in the study. The number of registered
patients eligible for follow-up was 537 in the control arm and
518 in the intervention arm, with ~15% of patients in each
arm lost to follow-up. Most outlets were in urban wards (70%
in both arms), had a single dispenser, and had at least some
ACTs in stock on the day of interview (Table 1). Of 51 dis-
pensers in the control arm and 59 in the intervention arm,
~80% in both arms were female and had a low-level medical
qualification, mostly nurse assistants (Table 2). Though low in
both arms, more ADDOs in the control arm compared with
the intervention arm were able to show an accreditation cer-
tificate (43% versus 20%, respectively). However, the differ-
ence in the percentages of dispensers that had received
training on ACTs was not as pronounced (69% in the control
Table 1
Characteristics of accredited drug dispensing outlets (ADDOs)
Control Intervention
Number (N) 37 40
Number urban (%) 26 (70%) 28 (70%)
Median number of dispensers per
ADDO (range)
1 (1–3) 1 (1–4)
Number with one or more trained
medical staff (%)*
36 (97%) 37 (92%)
Number with any ACTs in stock
on day of interview (%)
35 (95%) 40 (100%)
Number with all four weight-based
packs in stock on day
of interview (%)
11 (30%) 14 (35%)
Median number of customers
purchasing ACTs in last 7 days
(range)
13 (0–82) 19 (0–147)
Number with ADDO accreditation
certificate (%)
16 (43%) 8 (20%)
Number with drinking water
available in ADDO (%)
30 (81%) 37 (93%)
*Medical staff is defined as pharmacists, pharmacist assistants, medical doctors, assistant
medical doctors, clinical officers, assistant clinical officers, midwives, nurses, nurse assistants,
and laboratory technologists. Most were nurse assistants or nurses.
ACTs = artemisinin-based combination therapies.
Figure 2. Content of text messages sent to dispensers in the intervention arm.
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arm versus 60% in the intervention arm), though the median
year of training was more recent in the control arm (2011
versus 2009).
Characteristics of patients were well balanced between arms
(Table 3). A high percentage of patients (36% in the control
arm and 38% in the intervention arm) had sought care before
attending the study ADDO, with most patients going to a kiosk
or general shop and only 7% of patients in the control arm and
4% in the intervention arm going to a public health facility.
Approximately 90% reported symptoms of fever or headache,
and approximately half had upset stomachs or nausea. Based
on anmRDT taken at the time of follow-up, 28% in the control
arm and 25% in the intervention arm tested positive, with only
1.4% and 1.6%, respectively, testing positive by study blood
smear. (Some degree of discrepancy is expected because of the
persistence of HRP2 detected by the mRDT.)
Seventy percent of dispensers received at least 75% of the
text messages. The median percentage of messages received
was 86%, with 20% of dispensers receiving no messages
(Figure 3). Table 4 presents results of the dispenser interviews
on knowledge of advice to provide patients when dispensing
AL. Dispensers in the intervention arm reported slightly
better knowledge of the correct AL regimen for adults in the
intervention arm compared with the control arm (90% versus
78%; adjusted prevalence ratio [aPR] = 1.2 (95% confidence
interval [CI]: 0.95, 1.5); p [adjusted] = 0.0748), though knowl-
edge of the correct regimen for a child aged four weighing
20 kg was lower than for adults in both arms (75% versus
64%; aPR = 1.2 [0.85, 1.7]; p [adjusted] = 0.2). Dispenser
knowledge was considerably higher in the intervention arm than
the control arm on advice to take AL with fatty food (60%
versus 20%; aPR = 3.4 [95% CI: 1.6, 7.1]; p [adjusted] < 0.0001)
and to continue to take AL if minor side effects occur (68%
versus 43%; aPR = 1.6 [95% CI: 1.0, 2.4]; p [adjusted] = 0.0188).
However, surprisingly high dispenser knowledge (87–99%) was
recorded in both arms on advice to complete treatment even if
feeling better, advice to return to the ADDO or go to a health
facility if the condition worsens, and advice to take the second
dose after 8 hours (Table 4). Knowledge on advising patients
to take a replacement dose in case of vomiting within half an
hour of taking a dose was lower (55% versus 50%), with no
difference observed between arms.
Table 5 shows that ~60% of patients in both arms reported
being told how to take AL correctly, with similar percentages
reporting being told to take the second dose after 8 hours and
to complete treatment even if feeling better, indicating that
dispensers were providing some advice even in the absence of
the intervention. However, no differences were found between
control and intervention arms for any piece of advice. Less
than 5% of patients in both arms reported being told about
vomiting, side effects, or taking AL with fatty food, and < 10%
in both arms took the first dose of AL at the ADDO.
There was no difference in patient adherence between
arms (Table 6). Completed treatment was 70% in the control
arm and 68% in the intervention arm (adjusted risk ratio
Table 2
Characteristics of dispensers (post-intervention)
Control Intervention
Total number of dispensers 53 59
Number interviewed (N) 51 59
Male (%)* 10 (20%) 13 (22%)
Age (%)*
Under 35 years of age 18 (35%) 23 (39%)
35–49 years of age 23 (45%) 17 (29%)
50 years and above 10 (20%) 19 (32%)
Number with a medical
qualification (%)*†
44 (86%) 47 (81%)
Socioeconomic status (%)‡§
1st quintile (most poor) 9 (18%) 13 (22%)
2nd quintile 12 (24%) 10 (17%)
3rd quintile 9 (18%) 13 (22%)
4th quintile 8 (16%) 14 (24%)
5th quintile (least poor) 12 (24%) 9 (15%)
Number that had attended
training on ACTs (%)*
35 (69%) 35 (60%)
Median year of training
(range)
2011 (2005–2012) 2009 (2001–2012)
*Data missing for one dispenser in intervention arm.
†Medical staff is defined as pharmacists, pharmacist assistants, medical doctors, assistant
medical doctors, clinical officers, assistant clinical officers, midwives, nurses, nurse assistants,
and laboratory technologists. Most were nurse assistants or nurses.
‡Data missing for one dispenser in control arm.
§Wealth quintiles determined using a principal component analysis of sampled dispensers
based on standard Demographic and Health Survey variables.
Table 3
Characteristics of patients
Control Intervention
Number (N) 451 453
Male 240 (53%) 211 (47%)
Age*
Under 3 years 81 (18%) 78 (17%)
3 years to under 8 years 104 (23%) 91 (20%)
8 years to under 12 years 41 (9%) 42 (9%)
12 years and above 225 (50%) 242 (53%)
Blister pack obtained
1 + 6 (6 tablets) 109 (24%) 107 (23%)
2 + 6 (12 tablets) 95 (21%) 88 (19%)
3 + 6 (18 tablets) 50 (11%) 43 (10%)
4 + 6 (24 tablets) 197 (44%) 215 (48%)
Patient (or caregiver if patient
below age 12) completed
primary school†
323 (72%) 343 (76%)
Socioeconomic status‡
1st quintile (most poor) 87 (19%) 94 (21%)
2nd quintile 99 (22%) 82 (18%)
3rd quintile 97 (22%) 84 (19%)
4th quintile 85 (19%) 96 (21%)
5th quintile (least poor) 83 (18%) 97 (21%)
Slept under any bed net
the night before the
follow up interview
321 (71%) 357 (79%)
Sought care before attending
study ADDO
171 (38%) 163 (36%)
Median days since illness
onset before seeking
care at ADDO§
1 1
Symptoms¶
Fever or headache 410 (91%) 416 (92%)
Respiratory 34 (8%) 34 (8%)
Stomach upset 220 (49%) 209 (46%)
Otherk 216 (48%) 211 (47%)
mRDT positive at follow up** 121 (28%) 108 (25%)
Blood smear positive
at follow up††
6 (1.4%) 7 (1.6%)
*Age categories based on recommended age breakdown for artemether-lumefantrine
(AL) blister packs in Tanzania.
†Caregiver education missing for 3 patients < 12 in intervention arm.
‡Wealth quintiles determined using a principal component analysis of sampled patients
based on standard Demographic and Health Survey variables.
§Eleven patients in control arm and 4 patients in intervention arm did not remember the
number of days after illness onset when they sought care at the study accredited drug
dispensing outlets (ADDO).
¶Percents do not add to 100% as patients experienced multiple symptoms.
kIncludes fatigue, body aches, dizziness, shaking, convulsions, unusually-colored urine,
yellow mouth/eyes/body, etc.
**Malaria rapid diagnostic test (mRDT) data missing for 12 patients in control arm and 12
patients in intervention arm.
††Blood smear data missing for 18 patients in control arm and 13 patients in intervention arm.
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[aRR] = 0.96 [95% CI: 0.82, 1.1]; p [adjusted] = 0.6), with a
similar percentage of patients adherent to each of the four
age-appropriate blister packs and no important differences
between arms. The mean number of doses taken by non-
adherent patients was four in both arms, and the most common
reported reasons for non-adherence included planning to take
the medication later, forgetting to take the tablets, feeling
better, and other reasons (Figure 4). Timely completion was
much lower, with 33% of patients in both arms taking all doses
at appropriate times. A per protocol analysis, excluding patients
attending ADDOs where at least one dispenser did not receive
any messages, had no impact on results.
DISCUSSION
We have reported results from a cluster randomized trial of
a text message intervention directed at drug shop dispensers
to improve patient adherence to ACTs in Tanzania. The
intervention increased dispenser knowledge of some compo-
nents of advice to provide patients when dispensing AL, but
knowledge of other components was already very high in the
absence of the intervention. The improvements in knowledge
did not translate into an increase in information patients
reported receiving, even though patients commonly reported
receiving some advice. There was no difference in adherence
of patients to the ACT regimen between the arms.
Adherence by completed treatment was < 70% to ACTs
obtained from ADDOs, comparable to the 66% adherent by
the same definition in the study by Cohen and others (2012)11
in the private retail sector in Uganda. However, timely com-
pletion was only 33% in our study, indicating that even
patients who complete treatment may do so with poor adher-
ence to the recommended schedule. Both of these results are
comparable to reported adherence to ACTs obtained from
public health facilities, where studies under real life condi-
tions have found adherence of 64–77% for completed treat-
ment verified by pill count and 39–75% for timely completion
verified by pill count,5 including one study from Tanzania.35
Two other studies from public health facilities in mainland
Tanzania using different definitions and methods have reported
higher adherence (88.3% and 90%).33,34
Although the text message intervention targeting dispensers
was not effective at improving patient adherence, there was a
marked increase in dispenser knowledge of advising patients to
take AL with fatty foods or milk and to continue AL even if
minor side effects occurred. However, knowledge in both arms
was surprisingly high, particularly on advising patients to take
the second dose after 8 hours, to complete treatment even if
feeling better, and to seek further care if the condition worsens.
This could reflect the recent ADDO trainings in Mtwara, rais-
ing the possibility that the intervention’s impact could have
been different in the absence of recent training.
Knowledge did not necessarily result in the provision of
advice, even though some advice was provided. For example,
98% of dispensers in both arms knew it was important to
advise patients to complete treatment even if feeling better,
but only 60% of patients reported receiving this advice. Other
advice was much less commonly provided, with < 5% of
patients in both arms reporting being advised on what to do
in case of minor side-effects or vomiting, even though dis-
penser knowledge of this advice was much higher. This may
be because the dispensers did not deem the advice helpful to
their business or to the patients, as it could heighten a nega-
tive perception about the effects of their products. Dispensers
may have also perceived that clients were in a hurry or not
receptive to advice. Alternatively, patients or caretakers may
not have recalled the advice given to them several days
before. Exit interviews or mystery shopper surveys may have
been useful in assessing whether advice was communicated,
but these methods also have limitations, such as greater
potential for a Hawthorne effect and ethical challenges.
Figure 3. Percentage of text messages received by dispensers
in the intervention arm.
Table 4
Dispenser knowledge of correct advice (mean of cluster summaries)
Control* (N = 37)
% (SD)
Intervention* (N = 40)
% (SD)
Adjusted prevalence ratio
(95% CI)†
Adjusted
P value†
Proportion that gave correct advice on:
Correct AL regimen for adult‡ 78.4 (38.3) 90.0 (33.7) 1.19 (0.95, 1.49) 0.075
Correct AL regimen for a child (4 years and 20 kg)‡ 63.5 (46.6) 74.6 (40.4) 1.20 (0.85, 1.70) 0.2
Take with fatty food 20.3 (38.1) 60.0 (45.6) 3.41 (1.63, 7.12) 0.0001
Continue treatment if minor side effects occur 42.8 (42.8) 67.5 (45.2) 1.58 (1.03, 2.42) 0.019
Return to ADDO or go to a health facility if condition worsens 91.0 (25.3) 100.0 1.04 (0.84, 1.31) 0.7
Take second dose after 8 hours 86.9 (32.2) 97.5 (15.8) 1.11 (0.93, 1.32) 0.1
Take replacement dose in case of vomiting within half hour of taking dose 49.5 (45.7) 55.0 (46.4) 1.20 (0.77, 1.86) 0.4
Complete treatment even if feeling better 98.6 (8.2) 98.8 (7.9) 1.07 (0.88, 1.30) 0.5
*Total number of dispensers interviewed was 51 in the control arm and 59 in the intervention arm.
†Adjusted for accredited drug dispensing outlet (ADDO) accreditation, number of customers at ADDO purchasing artemisinin-based combination therapies (ACTs) (< 20 vs. 20 or more),
dispenser medical qualification, and training on ACTs
‡To be considered correct, responses had to identify artemether-lumefantrine (AL) as first-line treatment and specify that six doses should be taken, with each dose consisting of four pills
(adult) or 2 pills (child 4 years of age). Dose intervals considered correct included (A) taking a dose morning and evening for 3 days or (B) taking the second dose 8 hours after the first dose and the
remaining doses 12 hours apart (or morning and evening for the next 2 days).
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We intentionally avoided telling dispensers that the purpose
of our study was to improve patients’ adherence. Although
dispensers receiving text messages were aware that the content
focused on advising patients about the correct use of AL, we
did not mention the objective to dispensers in either arm to
avoid this information being relayed to patients, who might
then change their behavior because they expected their adher-
ence to be monitored.5 However, if this intervention were to be
scaled up outside the study context, one might include greater
emphasis on adherence and its value in communications with
dispensers, which might in turn increase the likelihood that
they would provide appropriate advice.
The evaluation of patient adherence relied on self-reported
data from patients or their caregivers, which may be subject to
recall and social desirability bias. We inspected blister packs
for the 80% of patients who could provide them and identi-
fied only 10 patients (1%) that had reported completing all
doses but had pills remaining. On the other hand, patients
may have removed pills from the packaging to consume at a
later time. Even though Swahili times of day, based on sunrise
and sunset, were used to assess timely completion, patients or
their caregivers may not have remembered when each dose
was taken or may have provided the expected responses to
avoid being seen as negligent.
A similar text message intervention targeting health
workers in public health facilities in Kenya found significant
improvements in health worker case management of pediatric
malaria.21 The primary outcome measure by Zurovac and
colleagues included completion of four treatment tasks (e.g.,
prescribing AL) and at least four of six dispensing and
counseling tasks, of which the biggest improvements were
seen in giving the first dose at the health facility and advising
patients to take the second dose after 8 hours, take each dose
after a meal, and what to do in case of vomiting. Although we
found strong evidence in the intervention arm of improved
dispenser knowledge of advice to take each dose with a fatty
meal, we recorded high dispenser knowledge in both arms of
advice to take the second dose after 8 hours and no difference
between arms in knowledge of advice on what to do in case of
vomiting. We also recorded < 10% of patients in either arm
taking the first dose of AL at the ADDO, even though drink-
ing water was available at many ADDOs. The contrasts
between our findings and those of Zurovac and colleagues
could reflect the private drug shop setting, as we found
patients’ relatives often seek care at ADDOs on behalf of
patients, in contrast to public health facilities where patients
themselves must be present for a clinical exam. Health
workers in public health facilities may also be more accus-
tomed to taking on advisory roles than dispensers in private
drug shops and less concerned with making a profit.37
Interventions involving training of dispensers in the private
retail sector, although limited in number, have improved dis-
penser knowledge across a range of diseases and settings, but
the impact of improved knowledge on dispenser and patient
behavior has been mixed.37,38 Even fewer studies have
reported effects of an intervention targeted at retail dispensers
Table 5
Patient report of advice received from dispenser (mean of cluster summaries)
Control* (N = 37)
% (SD)
Intervention* (N = 40)
% (SD)
Adjusted prevalence ratio
(95% CI)†
Adjusted
P value†
Explained correct dose regimen‡ 60.6 (21.2) 62.9 (21.5) 1.00 (0.84, 1.20) 0.9
Told to take second dose after 8 hours 64.2 (19.6) 63.0 (20.2) 1.00 (0.87, 1.15) 0.9
Told to complete treatment even if feeling better 61.3 (25.3) 59.3 (27.3) 0.94 (0.76, 1.17) 0.5
Told not to give drug to anyone else or save for future illnesses 41.3 (23.3) 35.1 (25.1) 0.88 (0.65, 1.18) 0.4
Told to return to ADDO or go to a health facility if condition worsens 34.1 (20.5) 35.0 (22.4) 1.01 (0.75, 1.35) 0.9
Told to take replacement dose in case of vomiting 3.3 (8.9) 3.2 (3.2) 1.48 (0.56, 3.90) 0.5
Told about possible side effects 2.8 (5.1) 2.0 (5.1) 0.60 (0.13, 2.77) 0.4
Told to take each dose with fatty food or milk§ 2.2 (8.4) 4.2 (9.7) 1.70 (0.40, 7.24) 0.4
First dose was observed at ADDO 5.4 (9.1) 6.9 (12.7) 1.32 (0.63, 2.76) 0.5
*Total number of patients interviewed was 451 in the control arm and 453 in the intervention arm.
†Adjusted for accredited drug dispensing outlet (ADDO) accreditation, number of customers at ADDO purchasing artemisinin-based combination therapies (ACTs) (< 20 vs. 20 or more),
dispenser medical qualification, and training on ACTs
‡To be considered correct, responses had to include the correct number of pills per dose for blister pack obtained, two doses per day, and 3 days duration (or 4 days to account for artemether-
lumefantrine [AL] obtained late on Day 1)
§If taking with any food or milk is considered correct, percentages increase to 60.2 (22.1) in the control arm and 58.8 (26.0) in the intervention arm, P = 0.8)
Table 6
Patient adherence (mean of cluster summaries)
Control* (N = 37)
% (SD)
Intervention* (N = 40)
% (SD)
Adjusted prevalence
ratio
(95% CI)†
Adjusted
P value†
Completed treatment‡ 69.8 (20.9) 68.3 (23.4) 0.96 (0.82, 1.12) 0.6
1 + 6 (6 tablets) 68.2 (33.3) 73.4 (30.9) 1.04 (0.81, 1.33) 0.7
2 + 6 (12 tablets) 62.0 (33.4) 70.7 (40.5) 1.10 (0.85, 1.43) 0.5
3 + 6 (18 tablets) 73.0 (35.7) 62.5 (39.7) 0.86 (0.66, 1.13) 0.4
4 + 6 (24 tablets) 73.8 (23.1) 67.8 (29.1) 0.89 (0.74, 1.08) 0.2
Timely completion§ 32.6 (18.4) 33.1 (21.6) 1.01 (0.76, 1.36) 0.9
1 + 6 (6 tablets) 37.2 (36.7) 26.4 (34.5) 0.67 (0.35, 1.28) 0.2
2 + 6 (12 tablets) 25.7 (24.9) 33.1 (36.6) 1.32 (0.86, 2.00) 0.4
3 + 6 (18 tablets) 35.5 (41.3) 37.9 (41.4) 1.02 (0.57, 1.81) 0.9
4 + 6 (24 tablets) 38.1 (27.6) 34.8 (29.3) 0.90 (0.57, 1.41) 0.6
*Total number of patients interviewed was 451 in the control arm and 453 in the intervention arm.
†Adjusted for accredited drug dispensing outlet (ADDO) accreditation, number of customers at ADDO purchasing artemisinin-based combination therapies (ACTs) (< 20 vs. 20 or more), and
patient education (patient or caregiver completed primary school).
‡Completed treatment unknown for three patients in the control arm and two patients in the intervention arm.
§Timely completion unknown for 10 patients in the control arm and 11 patients in the intervention arm.
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on patient adherence to antimalarial drugs. One study from
1998–2001 in Kilifi, Kenya found that trained shopkeepers
were willing to take on an advisory role, resulting in both
increases in advice and the proportion of patients taking ade-
quate doses of chloroquine and sulfadoxine pyrimethamine or
sulfadoxine-pyrimethamine.14 Although receiving instructions
has been associated with patient adherence to antimalarials in
several studies in the public and private sectors,11,39,40 other
factors might also influence patient adherence, including
patient education, higher socioeconomic status, treatment-
seeking behavior, understanding the instructions, knowledge
and perceptions of the illness or of the drug, and satisfaction
with information received or with the drug.5
The private retail sector is likely to continue to be an
important source of treatment of malaria and there is a need
to maximize patient adherence to ACTs. Given the effective-
ness of text message reminders on health worker case man-
agement in Kenya and the low cost of this intervention, there
is potential for further evaluations of text message interven-
tions targeted at dispensers in the private retail sector to
improve dispenser knowledge, advice provided, and patient
adherence, particularly in settings where dispensers have not
received recent training on malaria. Such interventions should
ensure message content addresses gaps in dispenser knowl-
edge and would benefit from additional research on dispenser
readiness to provide advice, and client receptivity to their
advice. There should also be further consideration of how best
to design the evaluation so that dispensers are motivated to
communicate the importance of adherence without biasing
study results.
The double gap between dispenser knowledge and provid-
ing advice and then patients receiving advice and being adher-
ent may also call for other interventions to enhance
adherence. Text message reminders to patients have been
shown to be a low-cost approach to improve patient adher-
ence to antiretroviral therapy for HIV41–43 and have been used
in two recent studies to increase patient adherence to malaria
test results and treatment (Goldberg J, unpublished data).44
However, scaling up a text message intervention targeted at
malaria patients in Tanzania would require an increase in per-
sonal mobile phone use among patients most at risk of
malaria,45 as only about half of the households in rural areas
own a mobile phone,29 and the phone may be shared among
household members. In contrast, nearly all dispensers censused
in Mtwara regularly used at least one mobile phone.
Other interventions that have been shown to improve
patient adherence to antimalarial drugs include packaging and
community education.46 ACTs are now mostly available in
factory packaged unit dose packs blister packs with illustrated
instructions, therefore additional room for improvement may
be limited. One possible modification could be improved
instructions in local languages. Community education through
communication campaigns could be helpful in emphasizing
the importance of taking all doses, but it may be challenging
to communicate the details of when and how to take each
dose to the general population. Finally, the introduction of
mRDTs in the private sector might have positive implica-
tions for patient adherence, especially if also combined with
dispenser advice.5
CONCLUSION
Text message reminders improved some aspects of dis-
penser knowledge of advice to provide to patients when dis-
pensing AL in the private sector. However, patients in the
intervention arm were not more likely to report receiving
improved advice and did not have higher adherence than
patients in the control arm. Adherence to AL among patients
in both arms was suboptimal, highlighting the need for studies
evaluating other interventions to improve adherence to ACTs
obtained in the private retail sector.
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